SCHEMBL4394159

SCHEMBL4394159

Cc1ccc(C(=O)Nc2ncc3c(C(=O)O)cn(C(C)(C)C)c3n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
RAB9A P51151 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
PKM P14618 1/20 0.51
P4HTM Q9NXG6 2/20 0.41
ADORA2A P29274 5/20 0.41
ADORA3 P0DMS8 4/20 0.41
ADORA1 P30542 4/20 0.41
NTRK1 P04629 3/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
RCE1 Q9Y256 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14566970 0.91 RAB9A (0.48) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3814978 0.90 RAB9A (0.47) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3822244 0.89 RAB9A (0.46) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3813353 0.88 MAPT (0.45) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3823247 0.88 MAPT (0.45) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3822085 0.86 KMT2A (0.44) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3814274 0.86 RAB9A (0.44) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3815728 0.86 ADRA2A (0.45) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL4398039 0.86 RAB9A (0.49) MAPTRAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL3818713 0.85 MAPT (0.43) MAPTRAB9AKMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306100-A1 METHODS OF TREATING SCHIZOPHRENIA LEXICON PHARMACEUTICALS, INC. 2009-12-10 US disclosed
US-20080153811-A1 methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. LEXICON PHARMACEUTICALS, INC. 2008-06-26 US disclosed
US-20070049608-A1 Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use LEXICON PHARMACEUTICALS, INC. 2007-03-01 US disclosed
US-20060258691-A1 Methods and compositions for improving cognition LEXICON PHARMACEUTICALS, INC. 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153811-A1 methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. CHAT, PSEN2, PSEN1 MAPT 7/4885RAB9A 1214/4885KMT2A 651/4885
US-20090306100-A1 METHODS OF TREATING SCHIZOPHRENIA CHAT, GAP43, GRIN2A MAPT 101/4885RAB9A 1054/4885KMT2A 464/4885
US-20060258691-A1 Methods and compositions for improving cognition PSEN1, PSEN2, APP MAPT 9/4885RAB9A 808/4885KMT2A 426/4885
US-20070049608-A1 Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use DPYD, TYMP, PNKP MAPT 1982/4885RAB9A 2588/4885KMT2A 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.